Adverum Biotechnologies Files Proxy Statement for Annual Meeting
| Field | Detail |
|---|---|
| Company | Adverum Biotechnologies, Inc. |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
Adverum's proxy is out - shareholders vote on exec pay & board soon.
AI Summary
Adverum Biotechnologies, Inc. filed a DEF 14A on April 28, 2025, for its annual meeting on June 17, 2025. The company, formerly known as Avalanche Biotechnologies, Inc., is seeking shareholder approval for matters related to its corporate governance and operations. The filing details executive compensation, board nominations, and other corporate actions requiring shareholder votes.
Why It Matters
This filing outlines key decisions shareholders will vote on, impacting the company's leadership, strategy, and financial direction for the upcoming year.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine but can reveal changes in executive compensation, board composition, or proposed corporate actions that may signal shifts in company strategy or governance.
Key Players & Entities
- Adverum Biotechnologies, Inc. (company) — Registrant
- Avalanche Biotechnologies, Inc. (company) — Former Company Name
- 20250428 (date) — Filing Date
- 20250617 (date) — Meeting Date
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information and solicit their votes for the annual meeting scheduled for June 17, 2025.
When was this filing submitted to the SEC?
This filing was submitted on April 28, 2025.
What was Adverum Biotechnologies' former name?
Adverum Biotechnologies, Inc. was formerly known as Avalanche Biotechnologies, Inc.
Where is Adverum Biotechnologies, Inc. headquartered?
The company's business and mail address is 100 Cardinal Way, Redwood City, CA 94063.
What is the fiscal year end for Adverum Biotechnologies, Inc.?
The company's fiscal year ends on December 31.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 regarding Adverum Biotechnologies, Inc..